A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Inclusion Criteria: * Histologically documented synovial sarcoma. * Patients with metastatic disease or locally recurrent disease who have failed or refused standard treatment. The disease must be measurable by RECIST. * Expected survival of at least 6 months. * Weight at least 35 kg. * ECOG performance scale 0-2. * At least 3 weeks since major surgery, and at least 3 weeks since completing radiation therapy or chemotherapy (6 weeks for patients receiving mitomycin C). * Resolution of toxicity from previous treatment to NCI-CTC grade 1 or less before treatment. * Adequate bone marrow, renal and hepatic function. * Able and willing to give valid written informed consent. Exclusion Criteria: * Clinically significant heart disease (NYHA Class III or IV). * Other serious illnesses, e.g. serious infections requiring antibiotics or bleeding disorders. * History of autoimmune disease. * Serious intercurrent illness, requiring hospitalization. * Patients with a second cancer diagnosis in the last five years, except for basal cell carcinoma, completely resected, or cervical carcinoma in situ (CIN), completely resected. * Known HIV positivity. * Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available. * Chronic use of immunosuppressive drugs such as systemic corticosteroids. * Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. * Lack of availa…